Ibrahim Fakhouri, MD
Family Medicine · Henderson, NVNPI 1720248206
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,152 and has fallen 89.5% since, to $120 in 2025.
Across 237 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$449
- Novartis$317
- Lilly USA, LLC$272
- GSK$194
- Biohaven Pharmaceuticals, Inc.$186
- plus $2K from 33 others
Across 24 payments — averaging $1956.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$46K
- Shionogi Inc$600
What the payments were for
- Food & beverage$4,430100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $1,027 |
| Novo Nordisk | 27 | $449 |
| Novartis | 15 | $317 |
| Lilly USA, LLC | 20 | $272 |
| GSK | 9 | $194 |
| Biohaven Pharmaceuticals, Inc. | 10 | $186 |
| AstraZeneca | 7 | $164 |
| Merck | 8 | $145 |
| Amgen(2 entities) | 7 | $140 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $139 |
| Pfizer | 7 | $137 |
| Zimmer Biomet | 1 | $137 |
| QOL Medical, LLC | 9 | $126 |
| Bayer | 5 | $105 |
| Exact Sciences | 6 | $96 |
| Esperion Therapeutics, Inc. | 4 | $84 |
| Antares Pharma, Inc. | 5 | $82 |
| Boehringer Ingelheim | 4 | $63 |
| Amarin Pharma, Inc. | 4 | $62 |
| Johnson & Johnson | 4 | $58 |
| Astellas Pharma US Inc | 2 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| IBSA Pharma Inc. | 2 | $38 |
| Tolmar, Inc. | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| Sanofi | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,430 in reported general payments places this provider in the 85th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 57 | $74,108 |
| OzempicSemaglutide | 27 | $47,518 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $18,010 |
| Tamsulosin Hcl | 76 | $1,493 |
| Testosterone Cypionate | 19 | $1,302 |
| Levothyroxine Sodium | 59 | $883 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 42 | $748 |
| Pantoprazole Sodium | 27 | $636 |
| Omeprazole | 40 | $569 |
| Atorvastatin Calcium | 40 | $503 |
| Alprazolam | 48 | $494 |
| Metformin Hcl | 54 | $484 |
| Metoprolol Succinate | 26 | $474 |
| Rosuvastatin Calcium | 59 | $467 |
| Oxycodone Hcl | 12 | $452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $272 | $74,10857 claims |
| Novo NordiskOzempic | $449 | $47,51827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 902 family medicine providers in Nevada.
Other family medicine in Henderson
- Badi EghterafiHenderson$38K
- Gautham ReddyHenderson$17K
- Rita ChuangHenderson$15K
- Yuan-Chung ChenHenderson$13K
- Travis HailstoneHenderson$8K
- Elena GarciaHenderson$7K
- Naz WahabLas Vegas$563K
- Jerry CadeLas Vegas$180K
- Nilesh GokalLas Vegas$75K
- Bayo Curry-WinchellReno$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.